Home

Codexis, Inc. - Common Stock (CDXS)

2.1100
-0.1800 (-7.86%)
NASDAQ · Last Trade: Apr 5th, 4:45 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close2.290
Open2.210
Bid2.020
Ask2.190
Day's Range2.000 - 2.250
52 Week Range2.000 - 6.080
Volume1,247,958
Market Cap136.39M
PE Ratio (TTM)-2.398
EPS (TTM)-0.9
Dividend & YieldN/A (N/A)
1 Month Average Volume1,177,141

Chart

About Codexis, Inc. - Common Stock (CDXS)

Codexis Inc is a biotechnology company that focuses on the development and application of protein engineering technologies to create innovative solutions for various industries, including pharmaceuticals, biotechnology, and agriculture. The company leverages its proprietary CodeEvolver platform to design and optimize enzymes for improved performance and efficiency, facilitating the production of active pharmaceutical ingredients and other bio-based products. With a strong emphasis on sustainability and reducing environmental impact, Codexis aims to transform traditional manufacturing processes through its engineered proteins, thereby advancing the future of bioeconomy and contributing to healthier living. Read More

News & Press Releases

12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · February 29, 2024
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via Benzinga · February 27, 2024
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · November 22, 2024
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (Nasdaq: CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (Nasdaq: ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.
By Artiva Biotherapeutics, Inc. · Via GlobeNewswire · October 22, 2024
CDXS Stock Earnings: Codexis Misses EPS, Beats Revenue for Q2 2024investorplace.com
CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
CDXS Stock Earnings: Codexis Beats EPS, Beats Revenue for Q1 2024investorplace.com
CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024
Recap: Codexis Q4 Earningsbenzinga.com
Via Benzinga · February 28, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · February 27, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 27, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · February 1, 2024
Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthroughbenzinga.com
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). 
Via Benzinga · December 27, 2023
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications.
Via AB Newswire · December 21, 2023
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionbenzinga.com
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Via Benzinga · December 14, 2023
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · December 14, 2023
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarketbenzinga.com
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading.
Via Benzinga · December 14, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 14, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · December 13, 2023
3 Synthetic Biology Stocks Likely to Mint New Millionairesinvestorplace.com
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.
Via InvestorPlace · November 29, 2023
The Next Nvidia: 3 AI Stocks That Could Break New Recordsinvestorplace.com
While trying to find the next Nvidia is a wildly risky proposition, these AI stocks to buy could be your ticket to extraordinary gains.
Via InvestorPlace · September 16, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · September 12, 2023
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1Mbenzinga.com
Via Benzinga · August 22, 2023
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Insteadbenzinga.com
Via Benzinga · August 21, 2023
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · August 14, 2023
Codexis' Strategic Focus: Discontinues Biotherapeutics Development, Lays Off 25% Of Employees, Cash Runway Into Mid-2026benzinga.com
Codexis Inc (NASDAQ: CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its 
Via Benzinga · July 21, 2023